GAITHERSBURG, MD (July 21, 2015) – MedImmune, the global biologics research and development arm of AstraZeneca, announced today that David Berman, M.D., PhD., has joined the company as Head of the Oncology Innovative Medicines unit (iMED) and Senior Vice President. In this role, he will lead the cross-functional teams responsible for the strategy, growth, and advancement of MedImmune’s biologics oncology portfolio, working closely with the oncology teams at AstraZeneca.
Dr. Berman will succeed Edward Bradley, M.D., who has announced his intention to retire at the end of 2016. Dr. Bradley will remain at MedImmune in an advisory role through the end of next year.
Dr. Berman was most recently Vice President and Head of the Immuno-Oncology Exploratory Development Team for Bristol-Myers Squibb (BMS). He has been with BMS since 2005 where he has held progressively senior-level positions in early and late-stage clinical development of the oncology portfolio. David had critical leadership roles in bringing the first immuno-oncology product through the U.S. FDA regulatory process, its subsequent global approvals and in translational medicine programs that explored the science of immuno-oncology. Prior to joining BMS, David was an attending pathologist at the National Cancer Institute of the National Institute of Health.
“We are thrilled to have world-renowned oncology expert David Berman join our team as we continue to progress our exciting combination focused immuno-oncology portfolio,” said Bahija Jallal, Executive Vice President, MedImmune. “David brings to us a wealth of experience, scientific leadership and industry respect, in all areas of areas of oncology research and development. He has big shoes to fill in taking the reins from Ed Bradley, but we are confident that he will serve as a strong and knowledgeable leader at this important time for our company.”
“I’d like to thank Ed Bradley for his years of service to MedImmune. Ed’s leadership and expertise have been instrumental in our successes to date in the oncology therapy area and he will be sorely missed.”
A graduate of the Massachusetts Institute of Technology, Dr. Berman earned his Ph.D. in the laboratory of Dr. Alfred Gilman at the University of Texas Southwestern Graduate School and his M.D. from the University of Texas Southwestern Medical School. He completed his residency in anatomic pathology at the National Cancer Institute and was a pathology fellow at The Johns Hopkins Hospital. David is a widely published author with more than 40 articles in such prestigious journals as Cell, Proceedings of the National Academy of Science, the Journal of Clinical Oncology, the Journal of Immunotherapy, and the British Journal of Haemotology. He was also part of the team that received the 2013 U.S. Prix Galien award for the best biotechnology drug.
NOTES TO EDITORS
MedImmune is the worldwide biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centers. For more information, please visit www.medimmune.com.
Tracy Rossin, MedImmune
Susannah Budington, MedImmune